RemeGen (09995) released a monthly update for the period ended 28 February 2026, reporting no changes in its overall share structure. The total authorized and registered share capital stood at 564.48 million shares, each with a par value of RMB1.

H shares (Stock Code: 09995), listed on The Stock Exchange of Hong Kong, remained at 208.58 million issued shares, with no treasury shares. The public float requirement was confirmed to be in compliance.

A shares (Stock Code: 688331), listed on the Shanghai Stock Exchange, remained at 355.90 million in authorized and registered shares. Of these, 355.70 million were in issue, and 0.19 million were held in treasury. No new shares were issued, and no treasury shares were canceled or transferred during the month.

Three A Share Incentive Schemes were noted, but no additional shares were issued in February 2026. The total number of shares that may be issued under these schemes stood at 2.32 million. The figures above reflect no material movements in issued or treasury shares for the reporting month.